antibody against ctmp  (Cell Signaling Technology Inc)

Journal: Oncotarget

Article Title: CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient

doi: 10.18632/oncotarget.10719

Figure Lengend Snippet: Univariate and multivariate Cox regression analysis for patients (n=369)

Article Snippet: After blocking, the slides were incubated with primary antibody against CTMP (Cell signaling), AKT-p473 (Cell signaling) and HER2 followed by biotin-conjugated secondary antibody, polymer-HRP and diaminobenzidine tetrahydroxychloride (DAB) solution.

Techniques:

Journal: Oncotarget

Article Title: CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient

doi: 10.18632/oncotarget.10719

Figure Lengend Snippet: A . CTMP, HER2 and AKT activity were analyzed in SkBR3 and BT-483 by Western blot. B . After 5 days trastuzumab treatment to SkBR3 and BT-483 cells, proliferation was examined using the MTT assay. Ectopic overexpression of different levels of CTMP in SkBR3 cells C . or knockdown of CTMP in BT-483 cells D . was used to modulate trastuzumab response as measured by the MTT assay. E . Western blots were performed to evaluate AKT, ERK and PDK1 and their activation in SkBR3 cells after transfection with GFP or GFP-CTMP. mean ± SEM; *, P < 0.05; ***, P < 0.001; n.s., no significance.

Article Snippet: After blocking, the slides were incubated with primary antibody against CTMP (Cell signaling), AKT-p473 (Cell signaling) and HER2 followed by biotin-conjugated secondary antibody, polymer-HRP and diaminobenzidine tetrahydroxychloride (DAB) solution.

Techniques: Activity Assay, Western Blot, MTT Assay, Over Expression, Activation Assay, Transfection

Journal: Oncotarget

Article Title: CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient

doi: 10.18632/oncotarget.10719

Figure Lengend Snippet: Western-blot was performed to determine AKT activity in CTMP-overexpressing SkBR3 (A) and in CTMP-silenced BT-483 cells (B) after trastuzumab treatment for 24 hours. C . CTMP-overexpressing SkBR3 and BT483 were treated with trastuzumab with or without AKT inhibitor IV, rapamycin and PD98058 for 72 hours and cell proliferation ability was determined by the MTT assay.

Article Snippet: After blocking, the slides were incubated with primary antibody against CTMP (Cell signaling), AKT-p473 (Cell signaling) and HER2 followed by biotin-conjugated secondary antibody, polymer-HRP and diaminobenzidine tetrahydroxychloride (DAB) solution.

Techniques: Western Blot, Activity Assay, MTT Assay

Journal: Oncotarget

Article Title: CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient

doi: 10.18632/oncotarget.10719

Figure Lengend Snippet: A . CTMP, p-AKT and HER2 expression level were examined in HER2-enriched patients by IHC. In each sample, 100 cells were scored from 0 to 3 and the sum was taken as the staining index. B . The expression levels were compared between trastuzumab responders and non-responders by student t test. C . Person's correlation was used to analyze the correlation between CTMP and p473-AKT. PD: progressing disease; NED: non-evidence of disease; mean ± SEM; *, P<0.05.

Article Snippet: After blocking, the slides were incubated with primary antibody against CTMP (Cell signaling), AKT-p473 (Cell signaling) and HER2 followed by biotin-conjugated secondary antibody, polymer-HRP and diaminobenzidine tetrahydroxychloride (DAB) solution.

Techniques: Expressing, Staining